DekaBank Deutsche Girozentrale Grows Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

DekaBank Deutsche Girozentrale increased its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 506,457 shares of the pharmaceutical company’s stock after acquiring an additional 4,948 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Vertex Pharmaceuticals were worth $233,370,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Modera Wealth Management LLC raised its position in shares of Vertex Pharmaceuticals by 0.7% in the third quarter. Modera Wealth Management LLC now owns 24,993 shares of the pharmaceutical company’s stock worth $11,624,000 after acquiring an additional 174 shares during the period. GHP Investment Advisors Inc. grew its stake in Vertex Pharmaceuticals by 64.5% in the 3rd quarter. GHP Investment Advisors Inc. now owns 102 shares of the pharmaceutical company’s stock valued at $47,000 after acquiring an additional 40 shares during the period. PFG Investments LLC raised its position in Vertex Pharmaceuticals by 1.8% during the third quarter. PFG Investments LLC now owns 1,773 shares of the pharmaceutical company’s stock worth $825,000 after acquiring an additional 31 shares during the period. Arkadios Wealth Advisors purchased a new position in Vertex Pharmaceuticals during the third quarter valued at $312,000. Finally, NorthCrest Asset Manangement LLC increased its stake in shares of Vertex Pharmaceuticals by 15.3% during the third quarter. NorthCrest Asset Manangement LLC now owns 1,418 shares of the pharmaceutical company’s stock worth $660,000 after purchasing an additional 188 shares in the last quarter. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. HC Wainwright reiterated a “buy” rating and set a $600.00 price objective on shares of Vertex Pharmaceuticals in a research note on Monday, October 21st. Barclays lowered Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and upped their price target for the company from $472.00 to $509.00 in a research report on Monday, August 5th. Guggenheim boosted their price target on shares of Vertex Pharmaceuticals from $450.00 to $558.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Royal Bank of Canada decreased their price objective on Vertex Pharmaceuticals from $431.00 to $425.00 and set a “sector perform” rating on the stock in a report on Friday, October 4th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $480.00 target price on shares of Vertex Pharmaceuticals in a research report on Tuesday, October 8th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $492.92.

Insider Buying and Selling

In other news, Director Bruce I. Sachs sold 5,295 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $508.00, for a total value of $2,689,860.00. Following the completion of the sale, the director now directly owns 40,000 shares of the company’s stock, valued at approximately $20,320,000. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Vertex Pharmaceuticals news, Director Sangeeta N. Bhatia sold 646 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $500.00, for a total value of $323,000.00. Following the sale, the director now owns 4,435 shares of the company’s stock, valued at approximately $2,217,500. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bruce I. Sachs sold 5,295 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $508.00, for a total value of $2,689,860.00. Following the completion of the sale, the director now owns 40,000 shares in the company, valued at approximately $20,320,000. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 12,005 shares of company stock worth $5,988,066 in the last 90 days. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Stock Up 1.2 %

VRTX stock opened at $477.70 on Friday. The company’s 50 day moving average is $475.61 and its two-hundred day moving average is $462.28. Vertex Pharmaceuticals Incorporated has a twelve month low of $341.90 and a twelve month high of $510.64. The company has a current ratio of 2.52, a quick ratio of 2.26 and a debt-to-equity ratio of 0.02. The stock has a market cap of $123.27 billion, a P/E ratio of 31.00 and a beta of 0.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Thursday, August 1st. The pharmaceutical company reported ($12.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($12.54) by ($0.29). The firm had revenue of $2.65 billion for the quarter, compared to analysts’ expectations of $2.66 billion. Vertex Pharmaceuticals had a negative return on equity of 2.45% and a negative net margin of 4.74%. The business’s revenue for the quarter was up 6.1% compared to the same quarter last year. During the same period in the previous year, the business posted $3.53 EPS. Research analysts expect that Vertex Pharmaceuticals Incorporated will post -2.11 earnings per share for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.